Because fibroblast growth factors (FGFs) modulate important functions of endothelial cells (EC) and smooth muscle cells (SMC), we studied FGF expression in human vascular cells and control or atherosclerotic arteries. All cells and arteries contained acidic (a) FGF and basic (b) FGF mRNA. Northern analysis detected aFGF mRNA only in one of five control arteries but in all five atheroma tested, while levels of bFGF mRNA did not differ among control (n = 3) vs. plaque specimens (n = 6). Immunolocalization revealed abundant bFGF protein in control vessels (n = 10), but little in plaques (n = 14). In contrast, atheroma (n = 14), but not control arteries (n = 10), consistently exhibited immunoreactive aFGF, notably in neovascularized and macrophage-rich regions of plaque. Because macrophages colocalized with aFGF, we tested human monocytoid THP-1 cells and demonstrated accumulation of aFGF mRNA during PMA-induced differentiation. We also examined the expression of mRNA encoding FGF receptors (FGFRs). All cells and arteries contained FGFR-1 mRNA.
Introduction
Fibroblast growth factors (FGFs) exert wide-ranging effects on various cell types (1) (2) (3) (4) . In vitro FGFs can stimulate proliferation, morphologic changes, and migration of vascular EC' and These data were presented in part in abstract form at the American Heart Association Scientific Session, November I [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] 1992 , New Orleans, LA.
Address correspondence to Dr. Peter SMC (1) (2) (3) (4) . In vivo these growth factors participate in development (1) (2) (3) (4) , vasculogenesis (5) , angiogenesis (6, 7) , and wound healing (6) . Acidic FGF (aFGF) and basic FGF (bFGF), also known as FGF-l and FGF-2, respectively (8) , are the best characterized members ofthe FGF family. A complex superfamily of cell surface receptors with tyrosine-kinase activity mediates FGFs' effects on target cells (9, 10) .
Recent studies support the involvement of aFGF and bFGF in vascular pathobiology. Animal experiments have established that these growth factors can foster re-endothelialization ( 11, 12) , mediate SMC replication (12) (13) (14) , and stimulate formation of vasa vasorum ( 14) in balloon-injured arteries. Although vascular EC and SMC can both produce and respond to aFGF and bFGF in vitro, information is incomplete regarding expression and localization of these growth factors and their receptors in either normal ( 15) or atherosclerotic ( 15, 16) human arteries. This study explored these issues.
We documented differential patterns of expression of FGF family members and of their receptors in cultured human EC and SMC and in atherosclerotic and control arteries. In particular, we found increased levels ofaFGF mRNA in human atheroma compared to nonatherosclerotic arteries and association ofaFGF protein with plaque microvessels and macrophages. In contrast, atheroma contained less immunoreactive bFGF protein than control arteries.
Methods
Cell culture. Human umbilical vein EC and aortic SMC were grown as previously described ( 17 ) . Human embryonal carcinoma cells (TERA-2), purchased from the American Type Culture Collection, Rockville, MD, were grown in medium 199 with 10% FCS, 100 U/ml penicillin, 100 gg/ ml streptomycin, and 0,25 ug/ ml amphotericin B (complete M199). Human skin fibroblasts (GM2037), purchased from the Human Genetic Mutant Cell Repository, Camden, NJ, were grown as previously described ( 18 ) . Human monocytes were isolated from leukocyte-rich fractions collected after leukapheresis from healthy donors. Mononuclear cells were layered onto Ficoll hypaque (Pharmacia LKB Biotechnology, Piscataway, NJ) and separated by centrifugation (2,500 rpm, 25 min). The mononuclear cell band was washed twice with HBSS without Ca2' and Mg2+, resuspended in medium RPMI 1640 with L-glutamine, 10% FCS, 25 mM Hepes, and 1% penicillin-streptomycin (complete RPMI) and permitted to adhere to polystyrene flasks. After 2 h, nonadherent cells were removed by washing gently three times with HBSS and medium was replaced. Mono- aFGF  GCTGCTGAGGCCATGGCTGAA  ACAGATCTCTTTAATCAGAAGAGACTG  489  40  bFGF  GGAGTGTGTGCTAACCGTTACCTGGCTATG  TCAGCTCTTAGCAGACATTGGAAGAAAAAG  243  41  FGF-3  ATGGGCCTAATCTGGCTGCTACTG  CAAACTCGCACTCGGCGCTGTAGT  349  42  FGF-4  GACTACCTGCTGGGCATCAAGCGG  GATGAACATGCCGGGGTACTTGTA  314  43  FGF-5  TCCAGCAGCAGACAGAGCAGCAGT  TGAGTTGGTATTTTTCCGAGGTGC  641  44  FGF-6  AGGCACCCGTGCCAACAACACGCT   TGACAGTCATGATCGGGGACACCT  484  45  FGF-7  CTTTGCTCTACAGATCATGCTTTC  TTGCCATAGGAAGAAAGTGGGCTG  542 (19) , adapted to long-term culture, were passaged in complete RPMI at a concentration of 2 x 105 cells/ml, but plated at higher density (6 X I05 cells/ml) for experimental use. All components used in tissue culture media were tested for endotoxin contamination using the chromogenic Limulus amebocyte lysate assay (QCL 1,000; M.A. Bioproducts, Walkersville, MD). All medium constituents yielded a final concentration of endotoxin less than 40 pg/ml. Arterial tissue. 14 carotid plaques were obtained at endarterectomy and processed within 2 h after surgery. Each specimen was rinsed twice in cold PBS to minimize blood residue, then a portion was snap-frozen in optimal cutting temperature tissue processing medium (OCT; Miles Diagnostics, Elkhart, IN) for immunohistochemical study and the remaining part was flash-frozen in liquid nitrogen and stored at -80°C for RNA isolation. Although the study did not include heavily calcified plaques, all atherosclerotic samples studied contained focal calcifications at microscopic examination. 10 control human arteries (4 aortas, 1 coronary, 1 subclavian, and 4 carotid arteries) were obtained from the New England Organ Bank or the Department of Surgery and handled similarly. Control arteries had a grossly normal appearance. At microscopic examination, six of them exhibited a degree of intimal thickening within normal limits for human arteries.
RNA isolationfrom cultured cells and tissue samples. In short-term experiments human monocytes and THP-1 cells were stimulated with: PMA, 25 nM (cat. no. P-8139, Sigma Chemical Co., St. Louis, MO); palmitoyl L-alpha-lysophosphatidylcholine, 100 MM (cat. no. L-5254, Sigma Chemical Co.); IFN-gamma, 500 U/ml (R&D Systems, Minneapolis, MN); LPS from Escherichia coli 055:B5, 10 ng/ml (cat. no. L-2880, Sigma Chemical Co.), and PDGF-BB, 10 ng/ml (Amgen Inc., Thousand Oaks, CA). Cells were harvested after 0, 2, 6, 10, 24, and 72 h oftreatment. In a longer time course study, THP-I cells were continuously stimulated with PMA, 100 nM for 4, 7, 14, and 17 d. Unstimulated control cells were harvested at day 0 and 17. During the course of long-term experiments culture medium, with or without addition of PMA, was replaced every other day. Total RNA from TERA-2 cells and human skin fibroblasts was prepared as described (17) . SMC were growth-arrested for 48 h (20) , stimulated for 6 h with PMA (25 nM), and extracted in GITC (21) . Tissue samples were homogenized in GITC and total RNA extracted (21) . RNA concentration was calculated from the absorbance at 260 nm. All RNA samples contained intact rRNA and lacked genomic DNA as evaluated by ethidium bromide staining of agarose-formaldehyde gels. Other RNA samples (hu-man brain, lung, skeletal muscle) used as positive controls in reverse transcription (RT)-PCR reactions, were purchased from Clontech, Palo Alto, CA.
Northern blot analysis. Equivalent amounts of RNA (10 or 15 gg, depending on the experiment) were separated on a 1.2% agarose gel containing 2.2 M formaldehyde. Gels were stained with ethidium bromide to verify loading of similar amounts of undegraded RNA. After although this transcript was detected in cultured aortic SMC ( Fig.   1 ). Both control and atherosclerotic arteries contained FGF-7 mRNA. Sources of positive control RNA were: human arterial SMC for aFGF, bFGF, FGF-5, and FGF-7; TERA-2 cells for FGF-4; and skeletal muscle for FGF-6. Identical volumes of the reaction mixture, but without addition ofcDNA, served as negative controls. PCR reactions using beta-actin specific primers demonstrated that equal amounts of cDNA had been used and similarly amplified. capillary transfer to nylon membranes (Hybond-N; Amersham Corp., Arlington Heights, IL), RNA was immobilized by short-wave UV irradiation (Stratalinker; Stratagene Corp., La Jolla, CA Qualitative analysis ofmRNA levels by RT-PCR. To answer questions regarding presence ofmRNA species, we used PCR amplification at 35 or 40 cycles. A lack of product at these levels of amplification using specific primers generally indicates little or no expression of the gene studied. However, quantitative comparisons between samples are uncertain at these high cycle numbers, because the plateau of expansion has usually been reached (22) . Sequence-specific primers used were designed to amplify selectively the messages coding for certain FGF family members, FGF receptors, and human beta-actin (Table I) . I Ml of cDNA prepared from THP-I cells was amplified at 40 cycles as previously described (22) In all cases, the estimated sizes of the amplification products detected corresponded well to the predicted sizes. Cloning into the plasmid pCRIOOO (Invitrogen Corp., San Diego, CA) and sequencing by the dideoxynucleotide chain termination method using an automated DNA sequencer (model 373A; Applied Biosystems, San Jose, CA) confirmed the identity of FGF-5 and FGF-7 PCR products. Similar analysis of the PCR product obtained using the FGF-3 primer pair indicated no correlation with FGF-3 mRNA. Therefore, data obtained using the FGF-3 primer pair are not reported.
Immunohistochemistry. Serial frozen sections (6 Mm) were cut onto poly-L-lysine coated slides and fixed in acetone. Incubation in 0.3% hydrogen peroxide for 20 min exhausted endogenous peroxidase activity. For each antibody the dilution that yielded optimal specific staining was determined in pilot experiments. Primary antibodies were di-SMC PLAQUE luted in PBS + 10% horse serum and applied to the sections for 1 h. Following two washes in Tris-buffered saline (TBS) with 2% horse serum, abiotinylated secondary antibody ( 1:100 dilution; Vector Laboratories, Burlingame, CA) directed against the species of origin of the primary antibody, was applied for 45 min. After two washes with TBS plus 2% horse serum and one in TBS alone, the ABC Elite solution (ABC Elite kit, Vector Laboratories) was applied for 45 min. The substrate 3-amino-9-ethyl-carbazole yielded a brown-red reaction product. Sections were lightly counterstained with methyl green or hematoxylin.
The following primary antibodies were used: affinity-purified rabbit polyclonal anti-human aFGF (10 Ag/ml; reference 23); mouse monoclonal anti-bovine bFGF (10 Ig/ml; Cat. no. 05-117; Upstate Biotechnology Inc., Lake Placid, NY); mouse monoclonal anti-muscle alphaactin, HHF35 (1:50 dilution; Cat. no. MA-93 1; Enzo Diagnostics, New York, NY); mouse monoclonal EBM-l 1 ( 1:4,000 dilution); mouse monoclonal anti-human von Willebrand factor ( 1:1,000 dilution, cat. no. M616; Dako Corp.). We also used Ulex europeus agglutinin I ( 1:800 dilution; Cat. no. L-1060; Vector Laboratories) to identify endothelial cells. Controls were performed using the same concentration of species and isotype-matched antibodies; rabbit polyclonal Ig fraction (Cat. no. X936; Dako Corp.) was used as control for the affinity-purified rabbit polyclonal anti-human aFGF antibody. These irrelevant antibodies did not stain the specimens examined. An additional control for aFGF specificity involved the use of a working dilution of the affinity-purified anti-aFGF polyclonal serum after overnight preabsorption with a 100-fold molar excess of human recombinant aFGF. Staining ofsamples with this serum was completely blocked. Comparative examination of serial sections stained with the above-mentioned antibodies permitted colocalization of growth factors and cell types. We used a semiquantitative grading system to analyze the immunohistochemical results. Two observers independently assigned a histologic score to each specimen, indicating extent of FGF staining associated with a given cell type (EC, SMC, macrophages) on a scale from 0 to 4. Grade 0 indicated that the cell type examined did not stain for the growth factor; grade 1 indicated positivity associated with less than 10% of a given cell type; grade 2 indicated positivity of 10-30% of a given cell type; grade 3 indicated positivity of 30-60% of a given cell type; and grade 4 indicated positivity of more than 60% of a given cell type. Results of this analysis are presented as mean±SEM. The grades assigned independently by both observers agreed within one grade; differences were resolved by joint examination. Recent hemorrhage was defined as macroscopically visible blood deposit within the vessel wall.
Old hemorrhage was defined as presence of hemosiderin, detected using Gomori's Prussian blue reaction identifying ferric ions.
Results
Cultured human EC and SMC express aFGF, bFGF, and low levels ofFGF-5 mRNA; SMC also express FGF-7 mRNA. We screened cultured human EC and SMC for expression of FGF family members using RT-PCR at 35 cycles of amplification ( Fig. 1 ). EC and SMC contained aFGF and bFGF mRNA, as previously reported ( 17), as well as low amounts of FGF-5 mRNA. SMC also expressed FGF-7 mRNA (Fig. 1 ).
Control and atherosclerotic human arteries express aFGF, bFGF, and FGF-7 mRNA. To determine the relevance ofthese observations in vitro to human atherogenesis, we investigated the expression of FGF family members in control and atherosclerotic human arteries using RT-PCR analysis at 35 cycles (Fig. 2) . All control and atherosclerotic human arteries contained aFGF, bFGF, and FGF-7 mRNA. Neither atherosclerotic nor control arteries contained FGF-5 mRNA (Fig. 2) , although both EC and SMC expressed this mRNA species in vitro ( Fig. 1) .
Human atheroma contain more aFGF mRNA than do control human vessels, but similar levels ofbFGF mRNA. Screening with PCR at 35 cycles ofamplification suggested that aFGF and bFGF mRNA were the most abundant FGF transcripts in human arteries. Because quantitation ofmRNA levels by PCR has certain limitations (22), we verified the expression of aFGF and bFGF mRNAs in vascular tissue by Northern analysis. This technique detected aFGF mRNA in five of five plaques tested, but only one offive control arteries had comparable levels ofthis message (Fig. 3 ). However, Northern analysis showed no consistent difference in the steady state levels of bFGF mRNA in control (n = 3) vs. atherosclerotic arteries (n = 6) ( Fig. 4 ). Cultured human EC and SMC express FGFR-I mRNA. To achieve a more complete understanding ofthe potential responsiveness ofvascular cells to FGFs, we studied the expression of FGFR family members in human cultured vascular EC and SMC using RT-PCR (Fig. 5 ). SMC contained FGFR-l mRNA and low levels ofFGFR-2 mRNA. EC expressed FGFR-I transcripts and low levels of FGFR-4 mRNA.
Control and atherosclerotic human arteries express similar levels ofFGFR-J mRNA. All control and atherosclerotic samples examined contained similar levels of FGFR-1 mRNA, as detected both by RT-PCR ( Fig. 6 ) and Northern analysis (Fig.  4 ). In addition, only control arteries contained FGFR-2 mRNA, while some control or atherosclerotic specimens contained FGFR-4 mRNA (Fig. 6 ).
Neovascularization and hemorrhages within plaques. The intima of all plaques (n = 14) contained microvascular plexi. These vessels generally had a thin wall composed of EC alone or with one or two layers of SMC (Fig. 7) . Microvascular plexi were found mainly at the base of plaque near the junction between intima and media ( 15/ 15 samples), or near the necrotic core ( 14/15 samples). These vessels localized within or adjacent to areas of macrophage infiltration in 13/15 samples. Nine plaques showed recent hemorrhages (9/15). All three plaques examined with Gomori's test had signs of old hemorrhages. In all three cases, the hemosiderin deposits were located near microvessels within lesions (data not shown). The specimens studied showed no areas of ulceration or plaque rupture. Distribution ofaFGF and bFGF in atherosclerotic and control arteries. Because aFGF and bFGF mRNA were the most abundant FGF transcripts in human arteries, we immunolocalized the corresponding proteins using specific antibodies. The EC lining the luminal surface of plaques or control arteries were sometimes incompletely preserved due to perioperative manipulation, but whenever present stained for aFGF both in control and atherosclerotic arteries ( Fig. 7 and 8 ). EC of lesional microvessels consistently stained for aFGF ( Fig. 7 , Table  II ). Medial SMC stained weakly for aFGF in both control and atherosclerotic arteries (Figs. 7 and 8; Table II ). Intimal SMC in plaques had even less aFGF staining than medial SMC of both control arteries and atheroma (Figs. 7 and 8; Table II ). Macrophage-rich areas within plaques stained for aFGF in 13/ 15 atherosclerotic arteries (Fig. 7 , Table II) . Also, scattered macrophages present in the thickened intima of control arteries colocalized with aFGF protein, but with less intense staining (Table II) .
Luminal EC, where preserved, stained for bFGF in both control and atherosclerotic arteries (Figs. 8 and 9 ). EC of plaque microvessels inconsistently stained for bFGF protein in 12/ 15 samples (Table II) . Medial SMC colocalized with bFGF in all control and atherosclerotic arteries (Figs. 8 and 9; Table  II ). Basic FGF staining also coincided with microvascular SMC of vasa vasorum (Fig. 9 , Table II ). However, intimal SMC, identified by staining for muscle alpha-actin, often (Table II) , and three plaques lacked any immunoreactive bFGF protein associated with intimal SMC (3/15; Fig. 9 ). Basic FGF colocalized with macrophages within atherosclerotic plaques (6/15), but staining for this protein was limited to less than 10% ofcells (Table II) . The few intimal macrophages in control arteries did not stain for bFGF (Table II) .
THP-J cells inducibly express aFGFmRNA. Because aFGF protein consistently colocalized with plaque macrophages, a cell type not heretofore known to express this gene, we tested whether mononuclear phagocytes could express the aFGF gene in vitro. Monocytes, monocyte-derived macrophages, and THP-1 cells, treated in vitro with PMA, IFN-gamma, LPS, lysophosphatidylcholine, or PDGF-BB for up to 72 h contained no aFGF mRNA (data not shown). However, prolonged treatment ( 14-17 d) ofTHP-1 cells with PMA induced accumulation of aFGF mRNA (Fig. 10 ). Unstimulated THP-1 cells at days 0 or 17 of culture did not contain this message. PMA-treated THP-l cells also expressed bFGF mRNA at days 7, 14, and 17 ofstimulation, while unstimulated THP-l cells at days 0 and 17 lacked this message (Fig. 10 ). Two independent experiments yielded similar results.
Discussion
Experimental studies in rats ( 13, 14) indicate a role for bFGF in initiating medial SMC proliferation after balloon injury. aFGF may also accelerate re-endothelialization and reduce intimal thickening after a similar type of injury (12) . there is little information available regarding the presence and distribution of these growth factors or of their receptors in either normal ( 15, 16) or atherosclerotic ( 16) human arteries. This study examined these issues to explore the potential roles ofFGFs in human vessels, and to integrate data obtained from animal studies with observations on human atherosclerosis. Advanced human atheroma usually contain microvessels that may contribute to plaque evolution or complication via intraplaque hemorrhages (24) (25) (26) (27) . Human atherosclerotic tissues contain thermolabile angiogenic activity (28) . We found that human atheroma contained more aFGF mRNA and protein than did uninvolved human arteries. We also observed a prominent association between aFGF protein and plaque regions rich in microvessels, suggesting that this growth factor participates in neovascularization oflesions. However, protein distribution does not necessarily imply biological activity, especially in the case of FGFs, which may be sequestered within cells or by binding to extracellular heparan sulfate proteoglycans. The observation that the introduction of constructs that direct the expression of a secreted form of aFGF promotes de novo formation ofintimal microvessels (7) provides direct evidence that this growth factor can cause intimal angiogenesis in vivo. Furthermore, Gordon and colleagues have demonstrated that dividing cells within human atheroma, identified by positive staining for the proliferating cell nuclear antigen (29) , localize preferentially in areas of microvascularization, an indication of ongoing growth factor activity in these loci (Gordon, D., unpublished observations). Hemosiderin deposits located near intimal microvessels, as reported by us and others (24, 25) , suggest the occurrence of prior hemorrhage from these structures. The newly formed vascular channels may be prone to rupture; consequent thrombosis in situ might activate thrombin-mediated events, such as SMC proliferation. Plaque microvessels also provide a large surface area, which can promote further recruitment of leukocytes via expression ofadhesion molecules (30) and/or production of chemoattractants, and thus contribute to the evolution of the atherosclerotic lesion.
We found that regions in plaques with abundant aFGF and microvessels often contained numerous macrophages. The colocalization of macrophages and immunoreactive aFGF in human atheroma was intriguing, since mononuclear phagocytes are not known to produce aFGF. We investigated this possibility using THP-1 cells, a homogeneous and well characterized monocytoid cell line adapted to long-term culture. Interestingly, induction of aFGF mRNA did not occur upon shortterm exposure to a wide range of stimuli, but required longterm treatment with PMA. Phorbol esters promote THP-l differentiation into macrophage-like cells (19) and induce expression of FGF genes in other human cell types (17, 18) . The requirement for prolonged stimulation may mimic in vitro the shift in phenotype of mononuclear phagocytes occurring during atherogenesis in vivo. Macrophages in lesions may be far removed from blood monocytes, as a result of chronic stimulation by a variety ofpathophysiologically relevant mediators, modeled here by phorbol ester. The inducible expression of the aFGF gene by a monocytoid cell line, together with the observation that in vivo plaque macrophages localize near or within areas rich in microvessels, suggests that these cells may contribute to the neovascularization characteristic ofadvanced atherosclerotic lesions by local release of angiogenic substances such as aFGF.
Macrophages can also produce other angiogenic factors (31) (32) (33) , such as bFGF (33) , in response to various stimuli (31 ) . Our analysis of human atherosclerotic samples showed less consistent colocalization of bFGF than of aFGF with plaque macrophages. However, we found substantial bFGF in the endothelium and in the medial layer of nonatherosclerotic human arteries, as previously reported in normal rat arteries (13) . Balloon withdrawal injury to the normal rat carotid causes intimal thickening resembling in some respects the restenotic lesion ofhuman arteries after angioplasty. Experimental data implicate bFGF in the initiation of medial SMC proliferation during this process in rats (1 1, 13 ) . However, because human atheroma contain scarce bFGF protein, as indicated here and elsewhere ( 16) , balloon injury to an advanced human lesion may release less bFGF than would injury to normal rat arteries. Our finding of scant bFGF protein in human atherosclerotic intima parallels the low levels of bFGF found in intimal lesions of balloon-injured rat carotid arteries ( 13) .
Although human atherosclerotic arteries contained less immunoreactive bFGF protein than control vessels, levels of bFGF mRNA did not differ significantly. Several factors could account for this apparent disparity between bFGF mRNA and protein levels. For example, the regulation of bFGF synthesis in atherosclerotic lesions might be posttranscriptional. Alternatively, ongoing biosynthesis of bFGF, reflected in mRNA levels, may not contribute substantially to the steady state level of bFGF protein, as the bulk of this growth factor present in normal arteries may represent preformed intracellular or matrixbound protein. The low level of bFGF protein documented in plaques could derive from depletion or consumption of bFGF stores rather than from reduced biosynthesis.
With respect to more recently recognized forms of FGFs, we found consistent expression of FGF-7 mRNA both in cultured SMC and in human arteries. FGF-7, also known as keratinocyte growth factor (34), selectively stimulates proliferation of epithelial cells (35) but has no mitogenic activity on human EC (35) or SMC (Rubin, J., personal communication). Furthermore, we found that human vascular cells and arten uv not contain mRNA for the FGFR-2 splice variant that specifically binds FGF-7 (Winkles, J., unpublished observations). Therefore, the biological relevance of FGF-7 within human arteries remains uncertain.
Growth factor responsiveness requires expression of an appropriate receptor. FGFRs constitute a family encoded by at least four different genes (36) (37) (38) (39) . Alternative splicing permits the assembly of multiple isoforms of each receptor (9, 10) . Furthermore, each FGFR can bind two or more FGFs, with graded affinity. FGFR-1, encoded by the flg gene, can bind both aFGF and bFGF. We found consistent expression of FGFR-1 mRNA in all control and atherosclerotic arteries examined. Several investigators have explored the use of toxins conjugated to FGFs as a strategy to prevent excessive proliferation of SMC after arterial injury. Our data suggest that this approach might not spare EC and SMC in normal human arteries, a point that merits further investigation.
